Pharmaceuticals

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

Early data for zolucatetide shows it shrinks tumors in a rare genetic disease, cracking a long-undruggable cancer target and offering new hope.

A novel oral drug for Alzheimer's avoids a key side effect of current therapies, as its 'detangler' platform shows promise for Parkinson's and other diseases.

A NY startup is using quantum computing and AI to fight aging at its source. Can Allosteric Bioscience's high-tech approach unlock a longer, healthier life?

With a unique entry-blocking drug, Bioxytran targets COVID, flu, and RSV, moving toward a pivotal trial that could redefine antiviral treatment.

The new iPSC-derived sensory neurons offer a reproducible human model, aiming to fix the broken pipeline of pain research and accelerate new analgesics.

Backed by JLL Partners, new platform Talica aims to unify the fragmented but vital surface science market for aerospace, pharma, and other high-tech industries.

Biotech firm ImmunoScape partners with a top US cancer center for a novel trial, backed by a strategic investment from actor Leonardo DiCaprio.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

Beyond the prescription pad, a new concierge program in Tucson integrates advanced diagnostics and lifestyle coaching to redefine sustainable weight management.

A new partnership automates data flow for 2,500+ research sites, promising near-perfect accuracy and faster drug development. Here’s how it works.

The wholesale distributor is integrating its offline supply chain with a B2B digital platform, aiming for massive growth in China's tech-driven health market.

A new partnership aims to use light and AI to break bottlenecks in drug development, promising to make personalized medicine faster and more accessible.

Scientists have supercharged a compound from rice bran, creating a potent new weapon against cellular aging that could reshape the future of nutrition.

Data shows Achieve Life Sciences' drug helps smokers quit, even after multiple failed attempts with other drugs, as a critical FDA decision looms.

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.